1. Scherk MA, Ford RB, Gaskell RM, et al. 2013 AAFP Feline Vaccination Advisory Panel Report. J Feline Med Surg 2013;15:785–808.
  2. Day MJ, Horzinek MC, Schultz RD, et al. WSAVA guidelines for the vaccination of dogs and cats. J Small Anim Pract 2016;57:E1–45.
  3. Volk JO, Felsted KE, Thomas JG, et al. Executive summary of the Bayer veterinary care usage study. J Am Vet Med Assoc 211;238:1275–82.
  4. Casal ML, Jezyk PF, Giger U. Transfer of colostral antibodies from queens to their kittens. Am J Vet Res 1996;57:1653–8.
  5. DiGangi BA, Levy JK, Griffin B, et al. Effects of maternally-derived antibodies on serologic responses to vaccination in kittens. J Feline Med Surg 2012;14:118–23.
  6. DiGangi BA, Levy JK, Griffin B, et al. Prevalence of serum antibody titers against feline panleukopenia virus, feline herpesvirus 1, and feline calicivirus in cats entering a Florida animal shelter. J Am Vet Med Assoc 2012;241:1320–25.
  7. Jakel V, Cussler K, Hanschmann KM, et al. Vaccination against feline panleukopenia: implications from a field study in kittens. BMC Vet Res 2012;8:62.
  8. American Animal Hospital Association Canine Vaccination Task Force, Welborn LV, DeVries JG, et al. 2011 AAHA canine vaccination guidelines. J Am Anim Hosp Assoc 2011;47:1–42.
  9. Brun A, Chappuis G, Precausta P, et al. Immunisation against panleukopenia: early development of immunity. Comp Immunol Microbiol Infect Dis 1979;1:335–9.
  10. Larson LJ, Newbury S, Schultz RD. Canine and feline vaccinations and immunology. In: Miller L, Hurley K, eds. Infectious disease management in animal shelters. Ames (IA): Wiley-Blackwell; 2009:61–82.
  11. Larson LJ, Schultz RD. Effect of vaccination with recombinant canine distemper virus vaccine immediately before exposure under shelter-like conditions. Vet Ther 2006;7:113–8.
  12. Srivastav A, Kass PH, McGill LD, et al. Comparative vaccine-specific and other injectable-specific risks of injection-site sarcomas in cats. J Am Vet Med Assoc 2012;241:595–602.
  13. Patel M, Carritt K, Lane J, et al. Comparative efficacy of feline leukemia virus (FeLV) inactivated whole-virus vaccine and canarypox virusvectored vaccine during virulent FeLV challenge and immunosuppression. Clin Vaccine Immunol 2015;22:798–805.
  14. Torres AN, O’Halloran KP, Larson LJ, et al. Feline leukemia virus immunity induced by whole inactivated virus vaccination. Vet Immunol Immunopathol 2010;134:122–31.
  15. Sharp NJ, Davis BJ, Guy JS, et al. Hydranencephaly and cerebellar hypoplasia in two kittens attributed to intrauterine parvovirus infection. J Comp Pathol 1999;121:39–53.
  16. Disease Information Fact Sheet: Feline Panleukopenia. J Feline Med Surg 2013;15: Supplementary File. This Disease Information Fact Sheet accompanies the 2013 AAFP Feline Vaccination Advisory Panel Report published in J Feline Med Surg 2013;15:785–808.
  17. Buonavoglia C, Marsiolio F, Tempesta M, et al. Use of a feline panleukopenia modified live virus vaccine in cats in the primary-stage of feline immunodeficiency virus infection. Zentralbl Veterinarmed B 1993;40:343–6.
  18. Reubel GH, Dean GA, George JW, et al. Effects of incidental infections and immune activation on disease progression in experimentally feline immunodeficiency virus-infected cats. J Acquir Immune Defic Syndr 1994;7:1003–15.
  19. Chalmers WS, Truyen U, Greenwood NM, et al. Efficacy of feline panleucopenia vaccine to prevent infection with an isolate of CPV2b obtained from a cat. Vet Microbiol 1999;69:41–5.
  20. Nakamura K, Ikeda Y, Miyazawa T, et al. Characterisation of crossreactivity of virus neutralising antibodies induced by feline panleukopenia virus and canine parvoviruses. Res Vet Sci 2001;71:219–22.
  21. Lappin MR. Feline panleukopenia virus, feline herpesvirus-1 and feline calicivirus antibody responses in seronegative specific pathogen-free kittens after parenteral administration of an inactivated FVRCP vaccine or a modified live FVRCP vaccine. J Feline Med Surg 2012;14:161–4.
  22. Truyen U, Addie D, Belák S, et al. Feline panleukopenia. ABCD guidelines on prevention and management. J Feline Med Surg 2009;11: 538–46.
  23. Huang C, Hess J, Gill M, et al. A dual-strain feline calicivirus vaccine stimulates broader cross-neutralization antibodies than a single-strain vaccine and lessens clinical signs in vaccinated cats when challenged with a homologous feline calicivirus strain associated with virulent systemic disease. J Feline Med Surg 2010;12:129–37.
  24. Bradley A, Kinyon J, Frana T, et al. Efficacy of intranasal administration of a modified live feline herpesvirus 1 and feline calicivirus vaccine against disease caused by Bordetella bronchiseptica after experimental challenge. J Vet Intern Med 2012;26:1121–5.
  25. Schultz RD. A commentary on parvovirus vaccination. J Feline Med Surg 2009;11:163–4.
  26. Wilson S, Greenslade J, Saunders G, et al. Difficulties in demonstrating long term immunity in FeLV vaccinated cats due to increasing age-related resistance to infection. BMC Vet Res 2012;8:125. DOI: 10.1186/1746-6148-8-125.
  27. Jirjis FF, Davis T, Lane J, et al. Protection against feline leukemia virus challenge for at least two years after vaccination with an inactivated feline leukemia virus vaccine. Vet Ther 2010:11:E1–6.
  28. Grosenbaugh DA, Leard T, Pardo MC, et al. Comparison of the safety and efficacy of a recombinant feline leukemia virus (FeLV) vaccine delivered transdermally and an inactivated FeLV vaccine delivered subcutaneously. Vet Ther 2004;5:258–62.
  29. Graf R, Guscetti F, Welle M, et al. Feline injection site sarcomas: data from Switzerland 2009-2014. J Comp Pathol 2018;163:1–5.
  30. Kass PH. Prevention of feline injection-site sarcomas: is there a scientific foundation for vaccine recommendations at this time? Vet Clin North Am Small Anim Pract 2018;48:301–6.
  31. Klingborg DJ, Hustead DR, Curry-Galvin EA, et al. AVMA Council on Biologic and Therapeutic Agents’ report on cat and dog vaccines. J Am Vet Med Assoc 2002;221:1401–7.
  32. Starr RM. Reaction rate in cats vaccinated with a new controlled-titer feline panleukopenia rhinotracheitis-calicivirus-Chlamydia psittaci vaccine. Cornell Vet 1993;83:311–23.
  33. Disease Information Fact Sheet: Feline Infectious Peritonitis. J Feline Med Surg 2013;15: Supplementary File. This Disease Information Fact Sheet accompanies the 2013 AAFP Feline Vaccination Advisory Panel Report published in J Feline Med Surg 2013;15:785–808.
  34. Little S, Levy J, Hartmann K, et al. 2020 AAFP feline retrovirus testing and management guidelines. J Feline Med Surg 2020;22:5–30.
  35. Fenimore A, Carter K, Fankhauser J, et al. Evaluation of intranasal vaccine administration and high-dose interferon- alpha2b therapy for treatment of chronic upper respiratory tract infections in shelter cats. J Feline Med Surg 2016;18:603–11.
  36. Helfer-Hungerbuehler AK, Spiri AM, Riond B, et al. No benefit of therapeutic vaccination in clinically healthy cats persistently infected with feline leukemia virus. Vaccine 2015;33:1578–85.
  37. Vogt AH, Rodan I, Brown M, et al. AAFP-AAHA feline life stage guidelines. J Am Anim Hosp Assoc 2010;46:70–85.
  38. Adams CL, Kurtz S. Skills for communicating in veterinary medicine. Parsippany (NJ): Dewpoint Publishing; 2017:112.
  39. Kass PH, Dent TH. The epidemiology of feline infectious peritonitis in catteries. Feline Pract 1995;23:27–32.
  40. Lappin MR, Andrews J, Simpson D, et al. Use of serologic tests to predict resistance to feline herpesvirus 1, feline calicivirus, and feline parvovirus infection in cats. J Am Vet Med Assoc 2002;220:38–42.
  41. Boenzli E, Hadorn M, Hartnack S, et al. Detection of antibodies to the feline leukemia virus (FeLV) transmembrane protein p15e: an alternative approach for serological FeLV detection based on antibodies to p15e. J Clin Microbiol 2014;52:2046–52.
  42. Moore GE, DeSantis-Kerr AC, Guptill LF, et al. Adverse events after vaccine administration in cats: 2560 cases (2002–2005). Vet Clin North Am Small Anim Pract 2010;40:393–407.
  43. Uhl EW, Heaton-Jones TG, Pu R, et al. FIV vaccine development and its importance to veterinary and human medicine: FIV vaccine 2002 update and review. Vet Immunol Immunopathol 2002;90:113–32.
  44. Yamamoto JK, Sanou MP, Abbott JR, et al. Feline immunodeficiency virus model for designing HIV/AIDS vaccines. Curr HIV Res 2010;8:14–25.
  45. Westman ME, Malik R, Hall E, et al. Determining the feline immunodeficiency virus (FIV) status of FIV-vaccinated cats using point-of-care antibody kits. Comp Immunol Microbiol Infect Dis 2015;42:43–52.
  46. Levy JK, Crawford PC, Tucker SJ. Performance of 4 point-of-care screening tests for feline leukemia virus and feline immunodeficiency virus. J Vet Intern Med 2017;31:521–6.
  47. DiGangi BA, Gray LK, Levy JK, et al. Detection of protective antibody titers against feline panleukopenia virus, feline herpesvirus-1, and feline calicivirus in shelter cats using a point-of-care ELISA. J Feline Med Surg 2011;13:912–8.
  48. Mende K, Stuetzer B, Truyen U, et al. Evaluation of an in-house dot enzyme-linked immunosorbent assay to detect antibodies against feline panleukopenia virus. J Feline Med Surg 2014;16:805–11.
  49. Gaskell R, Gettinby G, Graham S, et al. Veterinary Products Committee working group report on feline and canine vaccination. Vet Rec 2002;150: 126–34.
  50. Day MJ. Vaccine side effects: fact and fiction. Vet Microbiol 2006;117:51–8.
  51. Moore GE, HogenEsch H. Adverse vaccinal events in dogs and cats. Vet Clin North Am Small Anim Pract 2010;40:393–407.
  52. Clark N, Kushner NN, Barrett CB, et al. Efficacy and safety field trials of a recombinant DNA vaccine against feline leukemia virus infection. J Am Vet Med Assoc 1991;199:1433–43.
  53. Richards JR, Elston TH, Ford RB, et al. The 2006 American Association of Feline Practitioners Feline Vaccine Advisory Panel Report. J Am Vet Med Assoc 2006;229:1405–441.
  54. Davis-Wurzler GM. Current vaccination strategies in puppies and kittens. Vet Clin North Am Small Anim Pract 2006;36:607–40, vii.
  55. Vaccine-Associated Feline Sarcoma Task Force. The current understanding and management of vaccine-associated sarcomas in cats. J Am Vet Med Assoc 2005;226:1821–42.
  56. Hendrick MJ, Goldschmidt MH. Do injection site reactions induce fibrosarcomas in cats? J Am Vet Med Assoc 1991;199:968.
  57. Hendricks CG, Levy JK, Tucker SJ, et al. Tail vaccination in cats: a pilot study. J Feline Med Surg 2014;16:275–80.
  58. Shaw SC, Kent MS, Gordon IK, et al. Temporal changes in characteristics of injection-site sarcomas in cats: 392 cases (1990–2006) J Am Vet Med Assoc 2009;234:376–80.
  59. Macy DW, Hendrick MJ. The potential role of inflammation in the development of postvaccinal sarcomas in cats. Vet Clin North Am Small Anim Pract 1996;26:103–7.
  60. Day MD, Schoon HA, Magnol JP, et al. A kinetic study of histopathological changes in the subcutis of cats injected with nonadjuvanted and adjuvanted multi-component vaccines. Vaccine 2007;25:4073–84.
  61. Kang S, Southard T, Hume KR. DNA damage is a feature of feline injection-site sarcoma. Vet Comp Oncol 2016;15:518–24.
  62. Wilcock B, Wilcock A, Bottoms K. Feline postvaccinal sarcoma: 20 years later. Can Vet J 2012;53:430–4.
  63. Weese JS, Jack DC. Needlestick injuries in veterinary medicine. Can Vet J 2008;49:780–4.
  64. Centers for Disease Control and Prevention. CDC Vaccine Storage and Handling Toolkit. Available at: https://www.cdc.gov/vaccines/hcp/admin/ storage/toolkit/storage-handling-toolkit.pdf. Accessed September 24, 2019.
  65. Ford RB, Larson LJ, McClure KD, et al. 2017 AAHA canine vaccination guidelines. J Am Anim Hosp Assoc 2017;53:243–51.
  66. American Veterinary Medical Association. Rabies Vaccination State Law Summary. Available at: https://www.avma.org/Advocacy/StateAndLocal/ Documents/Rabies-state-law-chart.pdf. Accessed September 24, 2019.
  67. Rodan I, Sundahl E, Carney H, et al. AAHA and ISFM feline-friendly handling guidelines. J Feline Med Surg 2011;13:364–75.

Boehringer Ingelheim Animal Health USA Inc., Elanco Animal Health, Merck Animal Health, and Zoetis Petcare supported the development of the
2020 AAHA/AAFP Feline Vaccination Guidelines and resources through an educational grant to AAHA.